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Introduction
Vaults are the largest ribonucleoprotein particles described to
date. They were named for their typical lobular morphology,
which is reminiscent of the vaulted ceilings in cathedrals
(Kedersha and Rome, 1986). Mammalian vaults are composed
of multiple copies of three different proteins (p240, p193 and
p100) and several small untranslated RNA molecules of 88-
141 bases. The vault components assemble into a 13 MDa
hollow barrel-like structure of about 35 · 65 nm (Kong et al.,
2000; Kong et al., 1999) that is predominantly localized in the
cytoplasm. Nevertheless, a small part (~5%) of major vault
protein (MVP) is consistently associated with the nucleus
(Abbondanza et al., 1998; Chugani et al., 1993). Although the
cellular function of vaults is still unknown, their subcellular
localization and distinct morphology point to a role for vaults
in intracellular, particularly nucleo-cytoplasmic, transport
(Abbondanza et al., 1998; Chugani et al., 1993; Hamill and
Suprenant, 1997; Herrmann et al., 1999; Herrmann et al., 1996;
Kitazono et al., 2001; Kitazono et al., 1999; Li et al., 1999).
Vaults are frequently upregulated in multidrug-resistant cell
lines and tumors of different histogenetic origin. Furthermore,
they are highly expressed in tissues exposed to xenobiotics.
It has been suggested that vaults function in cellular
detoxification processes by transporting harmful agents away
from their cellular targets (for a review, see Scheffer et al.,
2000). 
The p100 subunit or MVP constitutes over 70% of the
molecular mass of vaults and is the main determinant of the
vault structure (Stephen et al., 2001). Interaction between MVP
molecules is mediated by the coiled-coil domain present in the
C-terminal half of the protein (van Zon et al., 2002). The p240
protein is identical to the telomerase-associated protein 1
(TEP1) and appears to be shared between at least two
ribonucleoprotein complexes, i.e. vaults and the telomerase
complex (Harrington et al., 1997; Kickhoefer et al., 1999b).
TEP1 is capable of binding vault RNA and is required for the
overall stability and stable association of the vault RNA with
the vault complex (Kickhoefer et al., 2001). The vault RNA
itself is thought to be a functional vault component rather than
a structural one (Kedersha et al., 1991; Kong et al., 2000;
van Zon et al., 2001). The p193 protein or VPARP [vault
poly(ADP-ribose) polymerase] exhibits a poly(ADP-ribose)
polymerase activity and can poly(ADP-ribosylate) MVP and,
to a lesser extent, itself (Kickhoefer et al., 1999a). Whether
there are other substrates for VPARP is presently unknown.
VPARP is a member of a growing family of enzymes, which
include PARP-1 and tankyrase (D’Amours et al., 1999; Smith,
2001). Although having a similarity of 29-60% between their
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Vaults are barrel-shaped cytoplasmic ribonucleoprotein
particles that are composed of a major vault protein
(MVP), two minor vault proteins [telomerase-associated
protein 1 (TEP1), vault poly(ADP-ribose) polymerase
(VPARP)] and small untranslated RNA molecules. Not all
expressed TEP1 and VPARP in cells is bound to vaults.
TEP1 is known to associate with the telomerase complex,
whereas VPARP is also present in the nuclear matrix and
in cytoplasmic clusters (VPARP-rods). We examined the
subcellular localization and the dynamics of the vault
complex in a non-small cell lung cancer cell line expressing
MVP tagged with green fluorescent protein. Using
quantitative fluorescence recovery after photobleaching
(FRAP) it was shown that vaults move temperature
independently by diffusion. However, incubation at room
temperature (21°C) resulted in the formation of distinct
tube-like structures in the cytoplasm. Raising the
temperature could reverse this process. When the vault-
tubes were formed, there were fewer or no VPARP-rods
present in the cytoplasm, suggesting an incorporation of
the VPARP into the vault-tubes. MVP molecules have to
interact with each other via their coiled-coil domain in
order to form vault-tubes. Furthermore, the stability of
microtubules influenced the efficiency of vault-tube
formation at 21°C. The dynamics and structure of the tubes
were examined using confocal microscopy. Our data
indicate a direct and dynamic relationship between vaults
and VPARP, providing further clues to unravel the function
of vaults.
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PARP domains, the PARP proteins in general do not resemble
each other outside the PARP domain, suggesting they have
separate cellular functions. Unique features of VPARP are a
BRCA1 C-terminus (BRCT) domain (aa 1-94) and an inter- a -
inhibitor domain (aa 616-1195); both domains may be involved
in protein-protein interactions. The C-terminus of VPARP (aa
1562-1724) has been shown to associate with the N-terminal
part of MVP (Kickhoefer et al., 1999a; van Zon et al., 2002).
Immunofluorescence and biochemical fractionation studies
clearly indicate that not all VPARP is bound to vaults; VPARP
is also present in the nuclear matrix and in distinct cytoplasmic
clusters (Kickhoefer et al., 1999a; Schroeijers et al., 2000) (this
manuscript). It is not clear whether VPARP fulfils separate
functions – unrelated to vault function – in its non-vault-
associated form.
Although the vault components and structure have been
characterized in detail, little is known about the intracellular
distribution and mobility of vaults in vivo and their relation to
non-vault-associated minor vault proteins. To visualize the
vault complex, we fused green fluorescent protein (GFP) to the
MVP. Bleaching experiments showed that vaults in the
cytoplasm are freely mobile and move by diffusion. However,
incubation of cells at 21°C resulted in the formation of highly
regular and dynamic vault-tubes. We present evidence for a
role of the cytoplasmic non-vault-associated VPARP-rods in
vault-tube formation.
Materials and Methods
Cell lines and culture conditions
The following human cell lines were used: the cervix epitheloid
carcinoma cell line HeLa, the non-small cell lung carcinoma cell line
SW1573 and its doxorubicin-selected multidrug resistant (MDR)
variant SW1573/2R120 (Kuiper et al., 1990). The cell line SW1573
was transfected with a construct encoding a C-terminal GFP-tagged
MVP or truncated MVP (aa 1-706); the resulting cell lines were
named SW1573/MVP-GFP and SW1573/MVP706-GFP. All cell lines
were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Life Technologies, Paisley, UK), supplemented with 10% (vol/vol)
fetal calf serum, 1 mM pyruvate, 100 U/ml penicillin and 100 m g/ml
streptomycin (Life Technologies) at 37°C under an atmosphere
containing 5% CO2. The drug-resistant cell line, SW1573/2R120, was
cultured in the presence of 120 nM doxorubicin. The transfected cell
lines were cultured in medium containing 200 m g/ml of G-418 (Life
Technologies). 
GFP-tagged MVP, MVP deletion constructs and transfection
An expression construct was generated by cloning the full-length
human MVP cDNA in frame to the 5 ¢ end of the enhanced GFP coding
sequence. Full-length MVP cDNA cloned in pBS-KSII was used as a
PCR template with the following primers: forward primer 5 ¢ -CCC-
AAGCTTGTCACCATGGCAACTGAAGAG and reverse primer
5¢ -CGGGATCCCGCAGTACAGGCACCACGTGG introducing a
HindIII and BamHI restriction site to facilitate cloning in pEGFP-N1
(Clonetech laboratories Inc., Palo Alto, CA). The PCR conditions
were as follows: 95°C for 2 minutes, then 35 cycles of 95°C for 30
seconds, 58°C for 1 minute and 72°C for 3 minutes followed by 72°C
for 10 minutes using Pfu DNA polymerase (Stratagene, La Jolla, CA).
The amplified DNA fragments were size fractionated by agarose gel
electrophoresis, isolated and extracted from agarose gel and ligated
into pCR Ò -Blunt (Invitrogen, Carlsbad, CA). The MVP fragments
were released from the vector by digestion with the appropriate
restriction enzymes and subsequently cloned into the GFP expression
vector. A cDNA fragment of human MVP encoding amino acids 1-
706 was amplified by standard PCR using 5¢ -CCCAAGCTTGTC-
ACCATGGCAACTGAAGAG as a forward primer and 5 ¢ -CCGG-
ATCCTCCAAAAGTTCCTTGCGAGC as reverse primer. To prevent
PCR artifacts we used Pfu polymerase combined with a low number
of PCR cycli. Amplified fragments containing appropriate restriction
sites were cloned in pZeroblunt (Invitrogen). Subsequently, the
HindIII-BamHI MVP fragments were cloned in the HindIII- and
BamHI-digested and dephosphorylated vector pEGFP-N1 (Clontech).
The resulting expression plasmid MVP706-GFP expresses GFP fused
to a MVP truncated at its C-terminal end. Transfection of the SW1573
cell line was performed by calcium-phosphate precipitation as
described previously (Parker and Stark, 1979). Approximately 48
hours after transfection, transfectants were selected by the addition of
800 m g/ml of G-418. The G-418-resistant and GFP-expressing cells
were isolated using a fluorescence-activated cell sorter (FACS) and
cultured in the presence of 200 m g/ml G-418.
Antibodies 
The mouse monoclonal anti-VPARP (mAb p193-4), mouse
monoclonal anti-MVP (LRP-56) and the rabbit polyclonal anti-MVP
were generated as described previously (Schroeijers et al., 2000). The
mouse monoclonal anti- b -tubulin and a species-specific isotype
antibody were purchased from the Sigma-Aldrich Corporation (St
Louis, MO), and the rabbit polyclonal anti-GFP was purchased at
Clontech Laboratories Inc. Species-specific anti-Ig antibodies
conjugated to tetramethyl rhodamine isothiocyanate (TRITC),
fluorescein isothiocyanate (FITC) or horseradish peroxidase (HRP)
were obtained from Jackson ImmunoResearch Laboratories Inc.
(West Grove, PA).
Immunoprecipitation, cell fractionation, SDS-PAGE and
western blot analysis
Antibodies were coupled to Protein A-Sepharose beads (Amersham
Pharmacia Biotech, Uppsala, Sweden) according to the
recommendations of the manufacturer. Immunoprecipitations from
protein lysates prepared in lysis buffer [50 mM Tris-Cl pH 7.4,
1.5 mM MgCl2, 75 mM NaCl, 0.5% (vol/vol) Nonidet P-40],
supplemented with a proteinase inhibitor cocktail (CompleteTM,
Roche, Mannheim, FRG) were carried out for 2 hours at 4°C.
Subsequently, the beads were washed with lysis buffer and twice with
PBS, after which the beads were suspended in protein sample buffer.
Immunoprecipitated proteins were analyzed by SDS-PAGE and
western blotting. A cellular fraction, enriched for vaults, was prepared
as follows: cells were harvested and resuspended in lysis buffer
supplemented with a proteinase inhibitor cocktail. All subsequent
steps were performed at 4°C. The cell lysate was incubated on ice for
5 minutes and cleared from nuclei by centrifugation for 20 minutes
at 20,000 g. The supernatant was centrifuged at 100,000 g for 90
minutes, resulting in a pellet fraction enriched for vaults. Equal
portions of the resulting supernatant and pellet fraction were subjected
to SDS-PAGE, after which the size-fractionated proteins were
transferred to nitrocellulose. The remaining protein binding sites on
western blots were blocked by Tris buffered saline/Tween 20 (TBST)
[50 mM Tris-Cl pH 7.5, 100 mM NaCl, 0.05% (vol/vol) Tween 20]
containing 5% (wt/vol) non-fat dry milk (Bio-Rad Laboratories,
Hercules, CA). Consecutively, primary and secondary antibody
incubations were carried out in the same buffer. Immune-complexes
were detected using the BM Chemiluminescence Blotting Substrate
(POD) kit (Roche, Mannheim, FRG) and visualized on HyperfilmTM
ECLTM (Amersham Pharmacia Biotech).
Fluorescence microscopy 
Cells were grown on poly-L-lysine-coated coverslips, after which they
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were fixed with 3% (vol/vol) formaldehyde in PBS for 20 minutes.
Subsequently, the cells were permeabilized by 1% (vol/vol) Triton-
X100 in PBS for 5 minutes. The remaining protein binding sites were
blocked with 1% (wt/vol) BSA in PBS for 30 minutes. Primary and
secondary antibody incubations were performed in the same buffer for
60 minutes at room temperature (21°C) using 25 m g/ml p193.4 mAb,
10 m g/ml LRP-56 and FITC- or TRITC-conjugated goat anti-mouse
Ig in a dilution as recommended by the manufacturer. Between each
antibody incubation step the coverslips were washed six times in PBS.
Coverslips were mounted on microscope slides in anti-fade [4%
(wt/vol) n-propyl gallate in glycerol] or VectaShield mounting
medium (Vector Laboratories Inc., Burlingame, CA). The fluorescent
staining pattern was studied using a Leica DMRXA microscope and
pictures were created using Leica QFish version V 2.3e. 
Confocal microscopy and fluorescence recovery after
photobleaching (FRAP)
A Zeiss (Jena, FRG) confocal laser-scanning microscope (CLSM)
equipped with a thermostatted stage was used for confocal
microscopy and FRAP experiments. Excitation illumination was by
an argon ion laser at 488 nm. Images were taken at a lateral resolution
of 102 nm using a 40· 1.3 n.a. objective. To determine cytoplasmic
mobility of vaults, a strip 2 m m wide spanning the width of the
cytoplasm was bleached by a short bleach pulse (200 milliseconds) at
relatively high laser intensity. Subsequently, fluorescence intensity
was monitored within the bleached strip at intervals of 100
milliseconds. The relative fluorescence intensity data was then fitted
to diffusion curves obtained by Monte Carlo computer simulation of
diffusion, immobile fraction and binding time in an ellipsoid
representing the cytoplasm with a sphere inside where the molecules
cannot go (representing the nucleus) (Hoogstraten et al., 2002). To
determine the dynamics of protein associated with vault-tubes, the
laser beam was focused in the center of a vault-tube and the region in
the beam was bleached for 4 seconds (at relatively low laser power).
Fluorescence redistribution was followed in time.
Results
GFP-tagged MVP proteins are incorporated into intact
vaults
To investigate the subcellular distribution and dynamics of the
vault complex, GFP was fused to the C-terminus (MVP-GFP)
of MVP. The subcellular distribution of the GFP fusion protein
expressed in the non-small cell lung carcinoma cell line
SW1573 was examined by fluorescence microscopy. A
particulate MVP-GFP fluorescence was distributed through the
cytoplasm with a denser staining in the perinuclear region (Fig.
1A,a). The fluorescent pattern was similar to the localization
of MVP in untransfected cells as detected by
immunofluorescence using a mouse monoclonal anti-MVP
(Fig. 1A,b). Incubation using an isotype control antibody
confirmed the specificity of the fluorescent signal (data not
shown). To verify whether the expressed GFP fusion protein
is actually incorporated into intact vault particles, we used
differential centrifugation. Vault particles have enough mass
to be pelleted from a crude cell lysate in a 100,000 g
centrifugation step. The GFP fusion protein was partly
recovered in the 100,000 g pellet fraction, together with
endogenous MVP (Fig. 1B). The ratio of GFP-tagged MVP
versus endogenous MVP in the pellet (P) fraction reflects their
expression levels as determined in the total lysate (TL),
indicating that both proteins are equivalent in competing for
incorporation into vault particles. Nevertheless, about 35-40%
of both the endogenous and GFP-tagged MVP is found in the
supernatant fraction. Similarly, on fractionation of SW1573
cells, part of the MVP (10-15%) was recovered in the
supernatant (S). The recovery of MVP and MVP-GFP in the
supernatant fraction may reflect the in vivo situation in which
a portion of the MVP is not incorporated into complexes large
enough to be pelleted at 100,000 g. Alternatively, it might
be a fractionation artifact. To ascertain that the MVP-GFP
is incorporated into genuine vaults, we performed an
immunoprecipitation with a rabbit polyclonal anti-GFP
antiserum. The subsequent analysis of the immunoprecipitates
by immunoblotting showed that the minor vault protein
VPARP is associated with the vaults containing MVP-GFP
(Fig. 1C). 
Dynamics of the vault complex measured by FRAP
We examined vault dynamics in living SW1573 cells
expressing MVP-GFP using fluorescence recovery after
photobleaching (FRAP). In a FRAP assay specifically suited
for determination of effective diffusion coefficients (Deff), we
compared the mobility of MVP-GFP (vaults) with that of free
GFP. As a control we used a SW1573 transfectant expressing
a GFP-tagged deletion mutant of MVP (MVP706-GFP) that is
Fig. 1. Incorporation of GFP-tagged MVP
molecules in vaults. (A) The SW1573
transfectant expressing MVP-GFP (a) was
examined by fluorescence microscopy. The
cell line SW1573 (b) was processed for
indirect immunofluorescence and stained
with anti-MVP (LRP-56). Bar, 10 m m. (B) Vault particles were
pelleted from a total cell lysate (TL) of SW1573, SW1573/MVP-
GFP transfectants and SW1573 transfectants expressing a GFP-
tagged truncated MVP (SW1573/MVP706-GFP) by a 100,000 g
centrifugation step. Immunoblotting using rabbit polyclonal anti-
MVP was performed to determine the presence of MVP and the
GFP-fusion proteins in the resulting pellet (P) and supernatant (S)
fractions. Note that SW1573/MVP-GFP and SW1573/MVP706-GFP
show two bands, representing endogenous (lower band) and GFP-
tagged MVP or truncated MVP (upper band). (C) Immunoblot
analysis showing the presence of the minor vault protein VPARP in
immunoprecipitates obtained from MVP-GFP transfectants using
anti-GFP (lane 2). Lane 1 contains control immunoprecipitates in
which a polyclonal rabbit pre-immune serum was used.
4394
not incorporated into vault particles, as shown by biochemical
fractionation (Fig. 1B).
In the cytoplasm a narrow strip (2 m m) was bleached by a
short laser pulse (200 milliseconds) at high laser intensity,
after which recovery of the fluorescent signal in the strip was
determined at intervals of 100 milliseconds. We observed a
full recovery of both GFP and MVP-GFP fluorescence,
indicating that all MVP-GFP, whether incorporated into vaults
or not, is mobile (Fig. 2A). The diffusion coefficients were
calculated from these measurements by least square fitting to
curves from computer simulations in which diffusion, bound
fraction and residence time were varied (see Materials and
Methods) (Hoogstraten et al., 2002). GFP molecules fitted best
to a model where all molecules were mobile and had a Deff of
14 – 2.4 m m2/s. The MVP-GFP data also fitted best to a model
where no bound fraction was present, and with a Deff of 2 – 0.4
m m2/s the MVP-GFP molecules were much slower than free
GFP. Using the effective diffusion coefficient of GFP
determined in our experimental set-up, we estimated that a
complex of 10-13 MDa will have a diffusion coefficient of
approximately 2 m m2/s. Therefore, we conclude that in vivo
most of the MVP-GFP molecules are incorporated into vault
particles. The effective diffusion coefficient of the mutant
MVP molecules (MVP706-GFP of about 107 kDa) as
determined by least square fitting to the computer simulation
curves was ~13 m m2/s. This value is close to that of free GFP,
confirming the fact that the MVP706-GFP molecules are
not incorporated into larger complexes. To check whether
vault movement was dependent on temperature, FRAP
measurements were performed at 37°C and 28°C. A relatively
small decrease in temperature (from 310 K to 301 K) has been
shown to have little effect on diffusion in living cells
(Hoogstraten et al., 2002; Phair and Misteli, 2000; Politz et
al., 1999). We observed no significant difference in vault
mobility in three independent experiments (Fig. 2B). These
results indicate that most of the vaults are freely mobile and
move by diffusion.
Redistribution of MVP-GFP into tube-like structures
Although the diffusion of vaults was not affected at 28°C, we
noticed a typical and highly consistent redistribution of the
MVP-GFP fluorescence when the transfected cells were
incubated at 21°C (room temperature). The characteristic
particulate fluorescent pattern observed in cells expressing
MVP-GFP cultured at 37°C is shown (Fig. 3A,a and Fig. 1A,a).
Incubation of these cells at 21°C for 30-60 minutes resulted in
the appearance of elongated fluorescent structures, resembling
tubes (Fig. 3A,d). These vault-tubes appeared in 50-80% of the
cells and disappeared within 30 minutes when the temperature
was raised to 37°C (Fig. 3A,g). Degrading vault-tubes seemed
to break open along their longitudinal axis, forming curled
sheets, which eventually dissolved to give rise to the regular
vault fluorescent pattern (data not shown). When SW1573/
MVP-GFP cells were stained for the minor vault protein
VPARP (Fig. 3A,b), the fluorescent pattern only partly
overlapped with the MVP-GFP fluorescence (Fig. 3A,c). In
addition to the fine particulate staining that colocalizes with
MVP-GFP, VPARP is also present in the nucleus and in distinct
elongated structures. These VPARP-rods are predominantly,
but not exclusively, present in the perinuclear region (Fig.
3A,b). 
When vault-tubes were allowed to form at 21°C, most of the
cytoplasmic VPARP-rods could no longer be detected
separately from the MVP-GFP fluorescence (Fig. 3A, e and f).
This indicates that the VPARP molecules of the rods are either
incorporated in the vault-tubes or that the tubes are formed at
the site of the VPARP-rods. By incubating cells at 21°C for a
short time (10 minutes) we were able to detect interactions
between the VPARP-rods and clusters of MVP-GFP molecules
(Fig. 3B). Vault-tubes were not yet formed, but an
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Fig. 2. Dynamics of the vault complex measured by FRAP. (A) The
graph shows the mobility of fluorescent MVP-GFP (red line)
compared with free GFP (green line) and a GFP-tagged truncated
MVP that is not incorporated into vaults (MVP706-GFP, blue line),
each measured in 12 cells. Fluorescence intensity before the bleach
pulse was set at 1. Note that the recovery of fluorescence is never
100% because of removal of fluorescence by the bleach pulse. This
effect differs between proteins depending on their residence time in
the strip during bleaching. (B) The redistribution of fluorescent
MVP-GFP within a bleached strip was monitored at 37°C (red line)
and at 28°C (blue line) with intervals of 100 milliseconds. The graph
depicts the data of an experiment in which 21 cells were measured.
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Fig. 3. Formation of vault-tubes. (A) SW1573/MVP-GFP cells were incubated at 37°C (a-c), at 21°C for 60 minutes (d-f) and at 37°C for 30
minutes after the treatment at 21°C (g-i). Shown is the MVP-GFP fluorescent signal (a,d,g), the indirect immunofluorescence staining for
VPARP (b,e,h) and the merged images (c,f,i). Incubation at 21°C resulted in the formation of large cytoplasmic, tube-like structures (vault-
tubes, d). Under the same conditions VPARP staining reveals a dramatic decrease in the number of non-vault-associated VPARP-rods. The
VPARP signal almost completely colocalizes with the tube structures (e and f). Both the MVP and VPARP distribution returns to normal when
the cells cultured at 21°C were placed at 37°C for 30 minutes (g-i). Bar, 10 m m. (B) Partial colocalization of GFP-tagged MVP (a and d) and
the VPARP-rods (b and e) in the merged picture (c and f) after incubation of SW1573/MVP-GFP cells at 21°C for 10 minutes. The arrowheads
point to sites where MVP-GFP clusters have formed, which are in close proximity to the VPARP-rods. Bars, 5 m m.
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accumulation of GFP-tagged MVP at the VPARP-rods was
observed (Fig. 3B). This implies a recruitment of MVP-GFP
(or vaults) to the VPARP-rods, which eventually may lead to
vault-tubes. Restoring the temperature to 37°C not only led to
the disintegration of the vault-tubes, but also to the
reappearance of the non-vault-associated VPARP-rods (Fig.
3A, h and i).
The subcellular localization of VPARP
We verified the presence of VPARP-rods in different –
nontransfected – cell lines. A similar subcellular distribution
of VPARP – a diffuse localization in both the nucleus and
cytoplasm and the presence of cytoplasmic VPARP-rods – was
observed in the nontransfected SW1573 and HeLa cells (Fig.
4A, a and b), as well as in the drug-resistant SW1573/2R120
and African green monkey kidney (COS) cells (data not
shown). The specificity of the VPARP staining was confirmed
by the absence of fluorescent signal when an isotype control
was used (Fig. 4A,c). The length of the VPARP-rods differed
in a cell-line-dependent manner. In particular, the differences
in length between the parental SW1573 and the MVP-GFP
transfected SW1573 pointed to a correlation between MVP
expression levels and the length of the VPARP-rods. We
therefore measured VPARP-rod length in SW1573 cells, its
drug-resistant, vault-overexpressing derivative SW1573/2R120
and the SW1573/MVP-GFP transfectant. The average length
varied from 1.5 m m in SW1573/MVP-GFP to 2.3 m m in
SW1573 cells (Fig. 4B, left-hand graph). Although the
orientation of the VPARP-rods may vary, the differences
in length were significant (P<0.05), confirming our visual
observations. The length of the VPARP-rods may have differed
because of the differences in the expression level of VPARP.
Nevertheless, western blot analysis indicated that the total
levels of expressed VPARP were similar in these cell lines (Fig.
4B, right-hand graph). As expected, MVP was upregulated in
the drug-resistant cells (usually around 1.5-fold compared with
the parental SW1573 cell line) and in the MVP-GFP-
transfectant cells (almost threefold). The size of the
cytoplasmic VPARP-rods appeared to inversely correlate with
the MVP expression levels.
The coiled-coil domain of MVP is necessary for vault-
tube formation
To exclude the possibility that the occurrence of vault-tubes
at 21°C is due to overexpression of MVP-GFP or the addition
of the GFP-tag, the formation of vault-tubes was investigated
in SW1573/2R120 and parental, nontransfected SW1573
cells (Fig. 5A). Vault-tubes, detected by indirect
immunofluorescence, were observed in both cell lines,
indicating that they are not caused by the overexpression of
GFP-tagged MVP. To test whether MVP-MVP interactions are
necessary for vault-tube formation we used the stable SW1573
transfectant expressing a GFP-tagged deletion mutant of MVP.
The MVP is truncated at its C-terminal end, resulting in a
partial deletion of the coiled-coil domain (MVP706-GFP). The
coiled-coil domain at the C-terminal half of MVP is essential
for the interaction of MVP molecules and consequently for the
assembly of vault particles (van Zon et al., 2002). The deletion
mutant is unable to interact with other MVP molecules and is
not incorporated into vault particles (Fig. 1B, Fig. 2A) (van
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Fig. 4. Cytoplasmic VPARP-rods
and their relation to MVP
expression levels. (A) Anti-VPARP
staining of untransfected SW1573
(a) and HeLa (b) cells showed a
normal VPARP distribution,
including the VPARP-rods.
Background staining was absent as
revealed by the staining of SW1573
cells with an isotype antibody (c).
Bar, 10 m m. (B) The left-hand
graph depicts the average length of
the VPARP-rods in untransfected
SW1573 cells, in its vault-
overexpressing drug-resistant
derivative SW1573/2R120 and in
the SW1573/MVP-GFP
transfectant. The numbers in the
bars indicate the number of
VPARP-rods measured. The data
were analyzed by the Student’s t-
test. The P-value was in all cases
below 0.05, indicating statistically
significant differences. The right-
hand graph shows the quantification
of the MVP (black bars) and
VPARP (gray bars) levels as
determined by immunoblotting (see
inlay; lane 1, SW1573/MVP-GFP; lane 2, SW1573/2R120; and lane 3, SW1573, with equal amounts of total protein loaded). The levels of
VPARP and MVP in the SW1573 cells are arbitrarily set at 1 and corrected for loading using the b -tubulin signal as a reference. Note that the
two protein bands visible in the MVP panel in lane 1 represent the endogenous MVP and the MVP-GFP fusion product.
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Zon et al., 2002). Expression of the truncated fusion protein
resulted in a less particulate, more diffuse fluorescent staining
pattern compared with the full-length MVP-GFP (Fig. 5B, a
and b). Incubation at 21°C led to the formation of GFP-labeled
vault-tubes in control cells, but not in the coiled-coil mutant
(Fig. 5B, c and d). This indicates that MVP molecules have to
interact with each other via their coiled-coil domain in order
to form vault-tubes. It is therefore probable that vault-tubes
contain intact vaults.
Dimensions and dynamics of the vault-tubes 
Confocal microscopy revealed that vault-tubes, which are
formed at 21°C, are cylinders with highly regular dimensions
(Fig. 6A). In living SW1573/MVP-GFP cells, the vault-tubes
had an average length of 7±2 m m (range 4.5-12 m m; n=16) and
a width of 1.5±0.3 m m (n=18). To study whether vault-tubes
are stable or dynamic structures (where MVP molecules bind
and release frequently), we performed FRAP experiments on
these structures (Fig. 6B). Surprisingly, approximately 100
seconds after the laser pulse the fluorescence in the bleached
area had completely recovered, indicating that the vault-tubes
are dynamic structures in which individual MVP molecules
have residence times of on average 100 seconds. Attempts to
quantify the fluorescent redistribution were hampered by the
fact that the vault-tubes are relatively narrow and tend to
move, leading to inaccurate measurements. In the current
experimental set-up we could not determine whether the
observed exchange of fluorescence was the result of individual
MVP-GFP molecules moving to and from vault-tubes or
whether it represented the exchange of whole vault particles.
Integrity of microtubules affects vault-tube formation 
Vaults have been suggested to function in cytoplasmic
transport, possibly via the microtubules (Hamill and
Suprenant, 1997; Herrmann et al., 1999). The question arises
as to what extent the microtubules are involved in the vault-
tube formation. There are no visible differences in the b -
tubulin staining in cells cultured at 37°C and 21°C, indicating
no dramatic effects on the microtubules when the temperature
drops to 21°C. To investigate whether microtubule
destabilization or stabilization results in vault-tube formation,
we treated SW1573/MVP-GFP cells with either 30 m M
nocodazole or 20 m M taxol for 60 minutes (Fig. 7). The
depolymerization of microtubules by nocodazole did not result
in vault-tube formation at 37°C, nor did the taxol incubation,
which stabilizes microtubules. However, when the treated cells
were incubated at 21°C for 60 minutes clear differences in the
amount of cells with vault-tubes were observed. Vault-tubes
were observed in approximately 80% (n=608) of the
nocodazole-treated cells. By contrast, 60% (n=684) of the
control cells contained vault-tubes, whereas only 3% (n=645)
of the taxol-treated cells showed vault-tube formation.
Apparently, the stability of the microtubules plays a significant
role in tube formation at 21°C. However, destabilization or
stabilization alone is not sufficient to initiate vault-tube
assembly at 37°C.
Discussion
Vaults are large ribonucleoprotein particles that may play a role
in intracellular transport; however, their precise cellular
function is unknown. Here, we investigated the dynamics and
subcellular distribution of vaults using GFP-tagged MVP
molecules expressed in non-small cell lung carcinoma cells.
All experiments shown were performed with SW1573 cells
expressing a C-terminal tagged MVP; however, identical
Fig. 5. Coiled-coil domain of MVP essential for incorporation into
vault-tubes. (A) Vault-tube formation, by a 60 minute incubation at
21°C, could be observed in nontransfected SW1573 (a) and
SW1573/2R120 (b) cells immunodetected with anti-MVP (LRP-56
mAb). Bar, 10 m m. (B) Stably transfected SW1573 cells expressing
either full-length MVP (a and c) or the amino acids 1-706 of MVP (b
and d) fused to GFP were incubated at 21°C for 60 minutes. The
GFP-tagged proteins in which a part of the coiled-coil domain of
MVP is deleted (MVP706-GFP) are not incorporated into vault-
tubes. Bar, 10 m m.
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results were found using an N-terminal-tagged MVP fusion
protein. Clearly, the outcome of the experiments was not
affected by the position of the GFP-tag. At room temperature
(21°C), we observed extensive rearrangements in vault
distribution and dynamics leading to the formation of vault-
tubes. Individual MVP molecules had to interact with each
other in order to form the vault-tubes, and the non-vault bound
VPARP pool is used during the vault-tube formation. We
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Fig. 7. Vault-tube formation
and the stability of
microtubules. SW1573/MVP-
GFP cells were cultured at
37°C for 60 minutes in the
absence (a and d) or presence
of 30 m M nocodazole (b and e)
or 20 m M taxol (c and f).
Subsequently, the cells were
placed at 21°C for 60 minutes
and monitored for vault-tube
formation by fluorescence
microscopy. Bar, 10 m m.
Fig. 6. Dimensions and dynamics of the
vault-tubes. (A) Images obtained by
confocal laser scan microscopy on living
SW1573/MVP-GFP cells cultured at 21°C
clearly show that vault-tubes are hollow
cylinders. Depicted are transverse and
longitudinal optical sections of the vault-
tubes. Bar, 5 m m. (B) Dynamics of the
vault-tubes were studied with FRAP.
Shown are images from a representative
FRAP experiment of a vault-tube before the
bleach pulse (pb), directly after bleaching
(0 s) and 50, 100 and 200 seconds after the
bleach pulse. The rapid recovery of
fluorescent staining in the bleached area
indicated that vault-tubes are dynamic
structures. Bar, 5 m m. 
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therefore believe that complete vault particles are incorporated
into the vault-tubes – a process that is completely reversible.
Most of our studies were performed with SW1573 cells
expressing MVP tagged with GFP. Therefore, we verified that
these tagged proteins are incorporated into genuine vaults. The
subcellular localization and appearance of the MVP-GFP
fluorescence is similar to the MVP pattern observed in
immunostained untransfected cells. Like regular vaults, the
GFP-tagged vaults can be precipitated by centrifugation at
100,000 g. These biochemical fractionation data show an
equal ratio of MVP and MVP-GFP in the pellet fraction
compared with the total lysate. This indicates that both
proteins are equivalent in competing for incorporation or
assembly. In both the parental and the MVP-GFP-
overexpressing cell line we found a fraction of MVP/MVP-
GFP in the supernatant after centrifugation. This might be an
artifact of the biochemical fractionation or it may represent an
in vivo situation in which not all MVP molecules are
incorporated into vault particles. Evidence that MVP-GFP
molecules are incorporated into vault particles came from the
in vivo FRAP measurements. Although it is likely that the
cytoplasmic organization (e.g. cytoskeleton, endoplasmic
reticulum) affects vaults kinetics, our data indicated that the
majority of MVP-GFP moved as free 10-13 MDa complexes.
However, owing to the limited resolution of the microscopic
methods used, we cannot completely rule out the possibility
that a small fraction behaves differently. The effective
diffusion coefficient of the expressed MVP-GFP was similar
to the one predicted for vault complexes (see Results section),
indicating that in vivo the majority of MVP-GFP is
incorporated into vault particles.
The intracellular localization of VPARP only partly
overlapped with that of MVP. Unlike vaults, VPARP is present
in the nucleus and in elongated structures in the cytoplasm
(VPARP-rods). In line with TEP1, which is a shared protein
with the telomerase complex (Kickhoefer et al., 1999b), the
non-vault-associated VPARP may have separate functions
independent of the vault complex. Nevertheless, our results
indicate a dynamic link between the non-vault-associated
VPARP fraction and vault particles. First, the length of the
VPARP-rod seems to be inversely correlated with the MVP
expression levels. Relatively high MVP expression levels
associate with short VPARP-rods. When more MVP is present
in a cell, more vault particles are formed (Siva et al., 2001;
Stephen et al., 2001) and probably more VPARP is
incorporated into these vaults. Consequently, less non-vault
bound VPARP is present in the cell, leading to shorter
VPARP-rods. Second, when vault-tubes are allowed to form
at 21°C, the VPARP-rods can no longer be detected separately
from the tubes. Probably, the VPARP is temporarily
incorporated in the vault-tubes. Both the localization of vaults
and the VPARP-rods are reversed when the cells are again
incubated at 37°C. Finally, we could detect clustering of
MVP-GFP on the VPARP-rods when cells were incubated at
21°C for a short time. This indicated the existence of a true
physical interaction between MPF-GFP molecules (or vaults)
and the VPARP-rods.
An intriguing question concerns the nature of the
cytoplasmic VPARP-rods. In a yeast-based two-hybrid system,
we showed previously that VPARP is not able to interact with
itself (van Zon et al., 2002). Therefore, VPARP-rods probably
need other proteins or structures to sustain themselves. The
VPARP-rods are relatively small (2 m m · 0.5 m m) compared
with the large vault-tubes (7 m m · 1.5 m m). Assuming that the
vault-tube is completely covered with vaults in a standing
position, one could calculate that there will be around 7500
vault particles per micrometer of vault-tube. Probably, the
symmetrical vault itself determines the morphology of the
vault-tubes. It was observed in vitro that vaults are able to
aggregate side-to-side in large pseudo-crystalline arrays
(Kedersha et al., 1991). We showed clustering of vault particles
in vivo, indicating that this might be a natural ability of the
vault particles. 
Because vault particles have been associated with
intracellular transport, a function in which the microtubules
may participate, we studied the involvement of the
microtubules in the vault-tube formation. One scenario might
be that the microtubules are damaged by the incubation at room
temperature and that this may cause the vault-tubes to form,
but depolymerization of the microtubules at 37°C did not result
in vault-tubes. However, when the cells were incubated at room
temperature, depolymerized microtubules had a stimulating
effect on vault-tube formation, and stabilization of the
microtubules had an inhibiting effect. The microtubule stability
plays a role in the vault-tube formation; however, other
impulses are necessary to initiate vault-tube assembly.
Lowering of the temperature also affects the efficiency of
enzymatic reactions and may influence protein conformation.
Preliminary results showed that small vault-tubes appear when
cells cultured at 37°C are treated with PARP-inhibitors, like 3-
aminobenzamide or DPQ [3,4-dihydro-5-[4-(1-piperidinyl)
butoxy]-1(2H)-isoquinoline], which suggests that the
inhibition of the enzymatic activity of VPARP may play a role
in tube formation. Although these results are interesting, also
the VPARP activity appears to be a small element in the
complex event of the vault-tube formation.
This work was supported by a grant to EACW from the Dutch
Organization for Scientific Research (NWO, 902-21-213). 
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